ELVN in the 13F filings
Enliven Therapeutics Inc · CUSIP 29337E102
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 19
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 0 listed it in both
- Shares listed
- 11,386,279
- combined, among listed positions
- Reported value
- $428m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 16 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -3,026,075.
Managers listing ELVN in Q1 2026
19 of 19 holders
Largest increases and reductions, by shares
Increases
- AllianceBernstein LPexisting position · 771,885 shares now+735,045
- Citadel Advisors LLCexisting position · 1,743,915 shares now+319,571
- Balyasny Asset Management LLCnew position · 310,025 shares now+310,025
- Schonfeld Strategic Advisors LLCnew position · 218,867 shares now+218,867
- D. E. Shaw & Co.new position · 193,531 shares now+193,531
Reductions
- Janus Henderson Group Ltdexisting position · 11,000 shares now-1,660,724
- Fidelity (FMR LLC)existing position · 6,829,246 shares now-278,389
- ExodusPoint Capital Management LPexisting position · 30,101 shares now-30,314
New positions and exits
New (7)
Exited (5)
- Point72 Asset Management LPwas $23m
- Capital Research Global Investorswas $20m
- Marshall Wace LLPwas $5.7m
- Tudor Investment Corpwas $457k
- Squarepoint Ops LLCwas $320k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2023 | 1 | $5.4m | n.a. | n.a. |
| Q4 2023 | 1 | $5.5m | 0 | 0 |
| Q1 2024 | 1 | $7.0m | 0 | 0 |
| Q2 2024 | 1 | $17m | 1 | 0 |
| Q3 2024 | 1 | $21m | 1 | 0 |
| Q4 2024 | 1 | $18m | 0 | 1 |
| Q1 2025 | 2 | $49m | 1 | 1 |
| Q2 2025 | 4 | $110m | 4 | 0 |
| Q3 2025 | 2 | $64m | 1 | 0 |
| Q4 2025 | 1 | $20m | 9 | 11 |
| Q1 2026 | 2 | $20m | 16 | 8 |
| Q2 2026 | 1 | $18m | 18 | 7 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ELVN and LLY →ELVN and JNJ →ELVN and VRTX →Choose a stock to compare with ELVN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ELVN, latest filings →Back to the 13F Explorer →